Jade Williams, Author at European Medical Journal - Page 9 of 22

Coin stacks

Genentech acquires Regor’s next-gen CKD inhibitor portfolio

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth $850M.

The word spotlight on a blue background

Spotlight: August 2024

Catch up on the top pharma news stories from August in our monthly round-up. From the latest on the spread of mpox to new treatment approvals, there’s plenty to discover.

Bavarian Nordic to manufacture 440,000 doses of mpox vaccine

Bavarian Nordic has entered into a significant agreement to manufacture 440,000 additional doses of its vaccine in response to the escalating mpox outbreak.

How creativity and innovation are revolutionising medical education

Isabel is joined by Tim Uden, Creative Director, EMJ to discuss the new frontier of medical education tools and skills – interactive content.

Pride Special: J&J's Edmond Chan on the value in being your authentic self

J&J’s Edmond Chan discusses how both the pharmaceutical and healthcare industries can do their best to support people from the LGBTQ+ community

HBA announces 2024 Woman of the Year

Alnylam’s Dr Yvonne Greenstreet is named Woman of the Year by the Healthcare Businesswomen’s Association

Spotlight: December 2023

Take a look at the top pharma news stories of the past month including projections for the years ahead, new investments, pricing negotiations and more.

Spoonful of technology: Oct-Dec 2023

Dive into the top technology stories of the past few months as GOLD explores the funding landscape and the latest innovations in the health tech market

Get ready for Gen Z doctors

A new generation of doctors is making their way into the workforce, but is the pharmaceutical industry ready to change its tactics to engage these younger HCPs?

VPAG: the UK's ticket to pharma superpower status?

A deal ends months of wrangling between the UK government and the ABPI, but what will it mean for the industry and the UK’s bid to become a life sciences superpower?